Questions and answers for health care providers: Renal dosing and administration recommendations for Peramivir IV
(15 November 2009: VIDYYA MEDICAL NEWS SERVICE) -- The dosing recommendations for peramivir in patients with varying degrees of renal impairment were derived based on the results of a pharmacokinetic study in renally impaired patients conducted by BioCryst. The results of the study indicate that the systemic exposure (as assessed by the area under the plasma drug concentration-time curve, called AUC) is increased by approximately 24%, 420% and 530% in patients with mild, moderate and severe renal impairment, respectively.
In patients with end stage renal disease (ESRD) receiving hemodialysis, a single dose of peramivir administered after dialysis resulted in a ~40-fold higher AUC relative to patients with normal renal function.
Renal dosing and administration recommendations for Peramivir IV
Return to Vidyya Medical News Service for 15 November 2009
© Vidyya. All rights reserved.
Information appearing on the Vidyya Medical News Service is not intended as a substitute for professional medical care. Seek professional medical help and follow your health care provider's advice.
Interested in subscribing to our daily e-mail newsletter? Send an email to Vidyya@vidyya.com with the word subscribe in the subject field.